GlassScriptPhysician profile
Troy Lee Bedinghaus
NPI 1831194075
$4,234.61
in general payments reported to CMS, 2019-2025
20 companies · $749 in 2025
The $749 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $157 · 2021: $541 · 2022: $629 · 2023: $847 · 2024: $641 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.61 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,480.65 | 2019-2025 | Precision7, Total30, Dailies Total1 Multifocal |
| Coopervision INC. | $978.32 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $267.97 | 2022-2025 | Infuse, Miebo, Biotrue One Day |
| Johnson & Johnson Surgical Vision, INC. | $265.93 | 2024-2025 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $203.93 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $185.93 | 2020-2023 | Cequa |
| Abbvie INC. | $162.90 | 2022-2023 | |
| Maculogix, INC. | $154.18 | 2019 | |
| Horizon Therapeutics Plc | $99.42 | 2023 | Tepezza |
| Optovue, INC. | $95.34 | 2019-2021 | |
| Konan Medical USA, INC. | $57.22 | 2019 | |
| Genzyme Corporation | $50.00 | 2025 | |
| Oyster Point Pharma, INC. | $48.08 | 2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $47.61 | 2020-2023 | |
| Abb Con-Cise Optical Group LLC | $45.78 | 2019-2024 | Contact Lens, Spectacle Lenses |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $21.92 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $21.55 | 2025 | Xdemvy |
| Shire North American Group INC | $17.93 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.25 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Bedinghaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.